A panelist discusses how new data from the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates tildrakizumab’s efficacy in treating nail psoriasis, with the 100-mg dose showing significant improvements in mNAPSI 75 and ViSENPsO responses at week 28 compared with placebo, potentially addressing a critical unmet need in psoriasis treatment.
Cefdinir Nearly Doubles Outpatient Uncomplicated UTI Treatment Failure Compared With Cephalexin
November 11th 2025Cefdinir is linked to nearly double the outpatient uncomplicated UTI treatment failure of cephalexin, with higher recurrence and increased resistance to other cephalosporins.
Read More